BioStock: AdjuTec Pharma enters phase I with novel AMR treatment

AdjuTec Pharma has launched a phase I clinical trial for its leading candidate, APC148, targeting a critical unmet need in combating antimicrobial resistance. This move into human trials is a significant milestone in demonstrating the safety and therapeutic potential of APC148, positioning AdjuTec as a key player in the fight against high-priority drug-resistant infections. CEO Bjørn Klem comments on the company’s strategy going forward.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/adjutec-pharma-enters-phase-i-with-novel-amr-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se